Micronet

SaverOne Enters into Term Sheet to Acquire Assets and Operations of Micronet Ltd.

Retrieved on: 
Wednesday, December 20, 2023
Marketing, Acquisition, Tel Aviv Stock Exchange, IP, Engineering, DDPS, Micronet, Camera, DMS

PETAH TIKVAH, Israel, Dec. 20, 2023 /PRNewswire/ -- SaverOne 2014 Ltd. (Nasdaq: SVRE) (TASE: SVRE), a technology company specializing in transportation safety solutions, today announced that it has signed a term sheet for the strategic acquisition of certain operations, products and IP of Micronet Ltd., a developer of advanced telematics systems cameras and Driver Monitoring Systems (DMS). Upon closing of this acquisition, it will broaden SaverOne's product portfolio and customer base, and is expected to accelerate SaverOne's go-to-market strategy in the US market.

Key Points: 
  • Micronet Ltd. is a publicly traded company on the Tel Aviv Stock Exchange, under the ticker MCRNT.
  • SaverOne's management expects the acquisition of the Micronet Ltd. operations and assets that are to be acquired, will be immediately accretive to SaverOne following the closing.
  • The majority of the consideration for the operations and assets will be contingent payments, related to the acquired operation's performance.
  • "We are very pleased to announce this first step towards the acquisition of certain Micronet assets, IP and operations which is expected to enhance and broaden SaverOne's product portfolio and customer base," commented Ori Gilboa, CEO of SaverOne.

InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform

Retrieved on: 
Monday, May 1, 2023
Mercy Hospital South, Marketing, Stenosis, Stroke, Mercy Hospital, TEL, NSPR, Patient, Physician, CAS, Micronet, EPS, IDE, FDA, Pharmaceutical industry, Medical device

TEL AVIV, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first carotid artery disease patient has been treated utilizing CGuard Prime, the company’s next generation CAS stent platform. The procedure was performed by Dr. Anish Thomas of Mercy Hospital South in St. Louis, MO, as part of InspireMD’s ongoing CGuardians U.S. IDE trial.

Key Points: 
  • The procedure was performed by Dr. Anish Thomas of Mercy Hospital South in St. Louis, MO, as part of InspireMD’s ongoing CGuardians U.S. IDE trial.
  • Marvin Slosman, chief executive officer of InspireMD, stated, “We are very pleased to have achieved this remarkable milestone – the successful first-in-human stenting procedure using CGuard Prime - as the final step in a lengthy development process as we work to advance new technology to build on our well established CGuard stent performance.
  • Our next generation feature set incorporated into CGuard Prime provides physicians with greater capabilities and confidence in the deployment of CGuard, our third generation MicroNet mesh protected stent.
  • The company will provide an additional update on this and other recent developments during its regularly scheduled Q1 2023 earnings conference call.

Actionable Intelligence Releases Special Report on Test Results Indicating Sources for Chips on Counterfeit Supplies

Retrieved on: 
Wednesday, February 22, 2023
Mobile, Wireless, Technology, Semiconductor, Office Products, Consulting, Other Technology, Professional Services, Software, Hardware, Retail, Micronet, HP, News, Printing, Risk, HP Inc., Cause of action, HP LaserJet, NineStar Connect, Video game, Amazon

“MicroNet Solutions’s test results are as surprising as they are consequential,” said Actionable Intelligence President Charles Brewer.

Key Points: 
  • “MicroNet Solutions’s test results are as surprising as they are consequential,” said Actionable Intelligence President Charles Brewer.
  • Chips that violate HP’s intellectual property (IP) put the business of third-party cartridge producers and their channel partners at risk.
  • We are providing our report at no cost because third-party supplies vendors need to know about MicroNet’s findings.
  • It is essential reading for anyone selling third-party supplies.”
    A free download of Actionable Intelligence’s 18-page report, “Testing Performed for HP Finds Ninestar and Subsidiaries Are Source for Counterfeit Chips,” is available at the firm’s website.

NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development

Retrieved on: 
Thursday, September 8, 2022
General Health, Medical Devices, Health, Health Technology, Cardiology, Partnership, Security (finance), Technology, Medtech, Stenosis, Xi, Solution, Sale, Micronet, Risk, Standard of care, CAD, Health, Forward-looking statement, SEC, U.S. Securities and Exchange Commission, Multimedia, Nasdaq, Company, Stroke, Compliance, III, Knowledge, Trademark dilution, Clinical trial, EPS, Industry, Embolism, MDR, NSPR, Patient, CRO, Pharmaceutical industry

(Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate medical device development and commercialization.

Key Points: 
  • (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate medical device development and commercialization.
  • We are thrilled that InspireMD has selected NAMSA as their strategic outsourcing partner of choice, commented Dr. Christophe Berthoux, NAMSA CEO.
  • Leveraging NAMSAs full continuum of development services, combined with our deep-rooted cardiovascular and neurovascular expertise, we look forward to helping accelerate InspireMDs new product development efforts, Dr. Berthoux concluded.
  • InspireMD has always sought ways to safely and efficiently accelerate product development through strategic outsourcing partners, and we have now found what we believe to be the ideal partner in NAMSA, commented Marvin Slosman, InspireMD CEO.

InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

Retrieved on: 
Thursday, July 14, 2022
Technology, SEC, Clinical trial, Security (finance), Sale, Compliance, U.S. Securities and Exchange Commission, EPS, Solution, University of Buenos Aires, Washington University School of Medicine, Company, Xi, Micronet, George Washington University School of Engineering and Applied Science, GLOBE, TCAR, Stroke, Nasdaq, Board certification, Risk, Forward-looking statement, Stent, Trademark dilution, TEL, University, Industry, Stenosis, DNA, General surgery, NSPR, Pharmaceutical industry, Dentistry

TEL AVIV, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke, today announced the appointment of endovascular pioneer Dr. Juan Parodi as a strategic advisor to the Company.

Key Points: 
  • TEL AVIV, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke, today announced the appointment of endovascular pioneer Dr. Juan Parodi as a strategic advisor to the Company.
  • Marvin Slosman, Chief Executive Officer of InspireMD, commented, Dr. Parodis world renowned achievements in the field of vascular surgery are remarkable, including having performed the first ever endovascular repair procedure in 1990.
  • He also performed the first carotid TCAR procedure in 1994, utilizing reverse flow for cerebral protection.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022

Retrieved on: 
Thursday, June 9, 2022
Clinical study design, Death, Stent, Restenosis, Company, Xi, Regression dilution, EPS, Forward-looking statement, Security (finance), U.S. Securities and Exchange Commission, Micronet, Nasdaq, Randomized controlled trial, Sale, Method, Male, Patient, GLOBE, Risk, Compliance, Incidence, TEL, SEC, Prevalence, Clinical trial, Teaching hospital, Myocardial infarction, Industry, NSPR, All-comers track meet, Safety, LINC, Congress, Online gambling, Risk management, Medical imaging, Veterinary medicine, Pharmaceutical industry, Stroke

TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke, today provided the following highlights from multiple presentations and live case transmission, all featuring its CGuard Embolic Prevention Stent System, from LINC 2022, which was held June 6-9.

Key Points: 
  • TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke, today provided the following highlights from multiple presentations and live case transmission, all featuring its CGuard Embolic Prevention Stent System, from LINC 2022, which was held June 6-9.
  • Of particular note, CGuard was featured in a very successful live case that clearly demonstrated the advantages of optimal vessel conformability with sustainable MicroNet mesh protection for best patient outcomes.
  • The patient was a 62 year old asymptomatic male with progressive and calcified internal carotid critical stenosis.
  • The procedure was successfully performed with the 10mm x 30mm CGuard EPS, obtaining an excellent angiographic result.

InspireMD Reports First Quarter 2022 Financial Results and Business Update

Retrieved on: 
Tuesday, May 10, 2022
COVID 19, Host, Biomedical sciences, KOL, Stent, Nasdaq, State university system, GLOBE, Holocene, Company, Stroke, Micronet, Food, Patient, TEL, Doctor of Philosophy, COVID, Clinical trial, Stenosis, FDA, Environment, Hospital, FACS, MD, Adoption, NSPR, IDE, Internet, FAHA, Conference, EPS, CEO, Growth, State University of New York, Pharmaceutical industry, Online gambling, Video game, Cleveland Clinic

First Quarter 2022 and Recent Highlights:

Key Points: 
  • First Quarter 2022 and Recent Highlights:
    CGuard revenues for the first quarter 2022 were $1,161,000, a 20% increase over the same period in 2021 on 1,910 stent systems sold.
  • Financial Results for the First Quarter ended March 31, 2022
    For the first quarter of 2022, revenue increased 17.6%, to $1,183,000, from $1,006,000 during the first quarter of 2021.
  • Gross profit for the first quarter of 2022 increased by $16,000, to $122,000, compared to a gross profit of $106,000 for the first quarter of 2021.
  • Management will host a conference call at 8:30AM ET today, May 10, 2022, to review financial results and provide an update on corporate developments.

InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results

Retrieved on: 
Tuesday, March 8, 2022
JACC, Host, Holocene, Adoption, Omicron, Micronet, Leadership, Patient, Clinical trial, Hospital, Industry, Stenosis, Food, Abbott, Coronavirus Scientific Advisory Board (Turkey), EPS, Board of directors, FDA, Growth, 2006–2007 economic sanctions against the Palestinian National Authority, Board, Goal, COVID-19, HAS, Conference, NSPR, Marketing, CEO, TCAR, TEL, Stroke, American College, American College of Cardiology, Nasdaq, IDE, GLOBE, Video game, Pharmaceutical industry, Animal, Director

--Management to Host Investor Conference Call Today, March 8, at 8:30am ET--

Key Points: 
  • Financial Results for the Fourth Quarter ended December 31, 2021
    For the fourth quarter of 2021, revenue increased by $1,222,000, or 773.8%, to $1,380,000, from $158,000 during the fourth quarter of 2020.
  • For the fourth quarter of 2021, gross profit increased $684,000, to $294,000, compared to a gross loss of $390,000 for the fourth quarter of 2020.
  • For the fourth quarter of 2021, total operating expenses were $4,225,000, an increase of $897,000, or 27.0% compared to $3,328,000 for the fourth quarter of 2020.
  • For the fourth quarter of 2021, financial expenses decreased by 7.6%, or $10,000, to $121,000, from $131,000 during the fourth quarter of 2020.

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

Retrieved on: 
Monday, February 28, 2022
GLOBE, Risk, Endarterectomy, Compliance, Physician, Regression dilution, Xi, Regulation of tobacco by the U.S. Food and Drug Administration, TEL, NINDS, Diabetes, Diet, Security (finance), Stroke, Industry, Company, Clinical trial, Sale, EPS, U.S. Securities and Exchange Commission, Stenosis, Food, Micronet, Tobacco, FDA, IDE, Nasdaq, Hypertension, Forward-looking statement, Patient, Technology, NSPR, SEC, Pharmaceutical industry

TEL AVIV, Israel, Feb. 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, today announced its CGuard Carotid Stent, utilizing its proprietary MicroNet mesh, will be included as a device option for stenting in the CREST-2 Trial. Following the approval of the Carotid Revascularization Endarterectomy or Stenting Trial (CREST-2) Investigational Device Exemption (IDE) supplement application from the U.S. Food and Drug Administration (FDA) last week, InspireMD will be evaluating strategic sites to enable expediated access.

Key Points: 
  • Following the approval of the Carotid Revascularization Endarterectomy or Stenting Trial (CREST-2) Investigational Device Exemption (IDE) supplement application from the U.S. Food and Drug Administration (FDA) last week, InspireMD will be evaluating strategic sites to enable expediated access.
  • The CREST-2 Trial is widely acknowledged as the most significant ongoing trial to scientifically investigate the optimal course of treatment to prevent stokes for asymptomatic patients with significant carotid disease.
  • The trial will enroll an estimated 2,480 participants which will remain in the study for 4 years following the start of intervention.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)

Retrieved on: 
Thursday, January 27, 2022
U.S. Securities and Exchange Commission, Trademark dilution, Compliance, Nasdaq, Physician, Solution, Forward-looking statement, Cardiology, SEC, Research, NSPR, Clinical trial, Sale, Method, Knowledge, Industry, Security (finance), Company, Micronet, Education, Communication, IAGS, Xi, Risk

For more information about the 16th Biennial Scientific Meeting, please refer to the conference website link.

Key Points: 
  • For more information about the 16th Biennial Scientific Meeting, please refer to the conference website link.
  • The IAGS is an international educational society of physicians and scientists interested in the healthsciences in the cardiovascular and related fields.
  • Society memberscooperate in the advancement of knowledge and education throughresearch, publication, study and teaching in the fields of cardiovasculardisease.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.